XML 52 R41.htm IDEA: XBRL DOCUMENT
v3.25.3

LICENSE AND DISTRIBUTION AGREEMENTS (Details) |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | ---
Sep. 16, 2024 USD ($) | Dec. 31, 2024 USD ($) | Sep. 30, 2025 USD ($) | Sep. 30, 2024 USD ($) | Mar. 31, 2023 USD ($) | Sep. 30, 2025 USD ($) | Sep. 30, 2025 EUR (€) | Sep. 30, 2024 USD ($) | Dec. 31, 2024 USD ($) | Dec. 31, 2023 USD ($) | Dec. 31, 2022 USD ($) | Jan. 24, 2022 USD ($)
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  | $ 2,261,642 |  |  |  | $ 11,139,956 |  |  |  |
Deferred revenue, current |  | $ 12,000,000 | $ 12,000,000 |  |  | $ 12,000,000 |  |  | $ 12,000,000 |  |  |
Receivables |  | 10,368,489 | 59,167 |  |  | 59,167 |  |  | 10,368,489 |  |  |
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  |  |  |  |  |  |  |  |  |  | $ 80,000,000
Milestones paid |  | 10,000,000 |  |  |  |  |  |  |  | $ 10,000,000 |  |
Upfront payment |  |  |  |  |  |  |  |  |  |  | $ 30,000,000 |
Deferred revenue liability |  | 0 | 0 |  |  | 0 |  |  | 0 |  |  |
Revenue |  |  | 0 | $ 2,300,000 |  | 0 |  | $ 11,100,000 | 40,000,000 |  |  |
Receivables |  | $ 10,000,000 |  |  |  |  |  |  | 10,000,000 |  |  |
Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, Japan |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  | 89,000,000 |  |  | 89,000,000 |  |  |  |  |  |
Upfront payment |  |  |  |  | $ 12,000,000 |  |  |  |  |  |  |
Deferred revenue liability |  |  | 12,000,000 |  |  | 12,000,000 |  |  |  |  |  |
Deferred revenue, current |  |  | 12,000,000 |  |  | 12,000,000 |  |  |  |  |  |
Binding Term Sheet With Nippon Shinyaku Co Limited Europe |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |
Potential additional development and sales-based milestone payments | $ 715,000,000 |  |  |  |  |  |  |  |  |  |  |
CSMC | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue liability |  |  | 40,000,000 |  |  | $ 40,000,000 |  |  |  |  |  |
Rome License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Notice period |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
JHU License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Notice period |  |  |  |  |  | 60 days | 60 days |  |  |  |  |
Threshold period to cure breach |  |  |  |  |  | 30 days | 30 days |  |  |  |  |
CSMC License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Notice period |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
Exosomes License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Notice period |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
Minimum | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Share of product revenue (in percent) |  |  |  |  |  |  |  |  |  |  |  | 30.00%
Minimum | Rome License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Minimum annual royalty payments | € |  |  |  |  |  |  | € 20,000 |  |  |  |  |
Maximum | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Share of product revenue (in percent) |  |  |  |  |  |  |  |  |  |  |  | 50.00%
Potential additional development and sales-based milestone payments |  |  |  |  |  |  |  |  |  |  |  | $ 605,000,000
Maximum | JHU License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Potential milestone payments |  |  | 1,850,000 |  |  | $ 1,850,000 |  |  |  |  |  |
Obtention of FDA Approval | JHU License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments to be made upon completion of certain phases |  |  | 1,000,000 |  |  | 1,000,000 |  |  |  |  |  |
Completion Of Phase Two Due | JHU License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Milestone payments to be made upon completion of certain phases |  |  | $ 500,000 |  |  | $ 500,000 |  |  |  |  |  |
Second Milestone Payment | Commercialization and Distribution Agreement with Nippon Shinyaku Co, Limited, United States |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  |  | $ 10,000,000 |  |  |
Patent rights | JHU License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Agreement effective period |  |  |  |  |  | 20 years | 20 years |  |  |  |  |
Non Payment of Royalties | CSMC License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination period |  |  |  |  |  | 30 days | 30 days |  |  |  |  |
Non Payment of Royalties | Exosomes License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Threshold period to cure breach |  |  |  |  |  | 30 days | 30 days |  |  |  |  |
CSMC Agreement Compliance | CSMC License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination period |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
CSMC Agreement Compliance | Exosomes License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Threshold period to cure breach |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
Material Breach Has Not Been Cured | CSMC License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination period |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
Material Breach Has Not Been Cured | Exosomes License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Threshold period to cure breach |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
Fails To Cure Breach after Notice From CSMC | CSMC License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Agreement termination period |  |  |  |  |  | 90 days | 90 days |  |  |  |  |
Fails To Cure Breach after Notice From CSMC | Exosomes License Agreement |  |  |  |  |  |  |  |  |  |  |  |
LICENSE AGREEMENTS |  |  |  |  |  |  |  |  |  |  |  |
Threshold period to cure breach |  |  |  |  |  | 90 days | 90 days |  |  |  |  |

X
- Definition Represents the agreement termination period. + References No definition available. + Details
Name: | capr_AgreementTerminationPeriod
Namespace Prefix: | capr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount paid for royalties on an annual basis. + References No definition available. + Details
Name: | capr_AnnualPaymentsForRoyalties
Namespace Prefix: | capr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition NA + References No definition available. + Details
Name: | capr_LicenseAgreementsLineItems
Namespace Prefix: | capr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of milestone payments during the period. + References No definition available. + Details
Name: | capr_MilestonePayments
Namespace Prefix: | capr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Milestone payments to be made upon successful completion of certain phases as per License agreement. + References No definition available. + Details
Name: | capr_MilestonePaymentsToBeMadeUponSuccessfulCompletionOfCertainPhases
Namespace Prefix: | capr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period for which agreement will be effective. + References No definition available. + Details
Name: | capr_PeriodOfAgreementWillBeInEffective
Namespace Prefix: | capr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of potential additional development and sales based milestone payments payable. + References No definition available. + Details
Name: | capr_PotentialAdditionalDevelopmentAndSalesBasedMilestonePayments
Namespace Prefix: | capr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of milestone payments payable under the JHU License Agreement. + References No definition available. + Details
Name: | capr_PotentialMilestonePayments
Namespace Prefix: | capr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of share of product revenue. + References No definition available. + Details
Name: | capr_ShareOfProductRevenuePercentage
Namespace Prefix: | capr_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Threshold period to cure breach. + References No definition available. + Details
Name: | capr_ThresholdPeriodToCureBreach
Namespace Prefix: | capr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront Payment made during the period + References No definition available. + Details
Name: | capr_UpfrontPayment
Namespace Prefix: | capr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition These lines are represents that notice period. + References No definition available. + Details
Name: | capr_WrittenNoticePeriod
Namespace Prefix: | capr_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_GrantsReceivableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedUnitedStatesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=capr_CommercializationAndDistributionAgreementWithNipponShinyakuCoLimitedJapanMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=capr_BindingTermSheetWithNipponShinyakuCoLimitedEuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=capr_CsmcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=capr_RomeLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=capr_JhuLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=capr_CsmcLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=capr_ExosomesLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | capr_MilestonePaymentsInPhasesAxis=capr_ObtentionOfFdaApprovalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | capr_MilestonePaymentsInPhasesAxis=capr_CompletionOfPhaseTwoDueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | capr_MilestonePaymentsInPhasesAxis=capr_SecondMilestonePaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=capr_UntilDateOfExpirationOfLastToExpirePatentWithinPatentRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=capr_NonPaymentOfRoyaltiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=capr_FailsToUndertakeCommerciallyReasonableEffortsToExploitPatentRightsOrFuturePatentRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=capr_MaterialBreachHasNotBeenCuredMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=capr_FailsToCureBreachAfterNoticeFromCsmcMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |